Allogeneic Umbilical Cord Blood Therapy for Stroke

MinYoung Kim, M.D.5 enrolled

Overview

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with stroke.

Stroke is one of the most common etiologies causing disability in developed countries. There remains no proven treatments except tissue plasminogen activator currently. Based on promising results of cell therapy in animal stroke models, efforts to apply cell therapy for patients with stroke has been made. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for stroke.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Stroke

Interventions

Allogeneic umbilical cord blood therapyPROCEDURE

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Ischemic or hemorrhagic stroke * Onset duration over 12 months * Hemisphere lesions except brain stem and cerebellar lesions * National Institute Health Stroke Scale: 10 to 15 Exclusion Criteria: * Possibility of hypersensitivity drugs used in this study * Uncontrolled hypertension or cardiovascualr diseases * Malignant cancer * Renal or hepatic dysfunction (Consultation to specialist in nephrology or gastroenterology in case of renal or hepatic dysfunction) * Severe pulmonary dysfunction * Traumatic brain injury * Lack of matched UCB

Locations (1)

CHA Bundang Medical Center, CHA University

Seongnam-si, Gyeonggi-do, South Korea